Therefore, and in line with our results for breast cancer DCCs, IL-6 trans-signaling via binding of IL-6 to sIL-6RA and subsequent binding to gp130 is much more likely involved in pathway activation than classical IL-6 signaling. The gene discussed is IL6; the disease is breast carcinoma.